Obesity and asthma are common and debilitating conditions that are especially prevalent in urban Hispanic and African American populations[@b1][@b2]. Over the past decade, obesity is recognized as an independent risk factor for asthma[@b3][@b4][@b5][@b6][@b7] and is associated with greater morbidity compared to asthma in normal-weight children[@b8][@b9]. Mechanistic studies suggest that obesity-associated asthma is a distinct entity, but its pathophysiology remains poorly defined[@b10].

While obesity is a chronic inflammatory state characterized by leptin-mediated T helper (Th)1 inflammation[@b11], "classic" childhood asthma is predominantly allergic in nature with a relative bias toward a Th2 phenotype[@b12]. In contrast to Th2 inflammation, non-atopic inflammation[@b13][@b14] with Th1 polarization[@b15] which correlated with lower airway obstruction has been reported in obese asthmatics[@b15], lending support to the hypothesis that obesity-associated asthma is a distinct asthma phenotype.

Both asthma and obesity are multifactorial conditions and likely reflect a combined effect of genetic and environmental modulation[@b16][@b17]. Epigenetic dysregulation manifested by DNA methylation, potentially reflecting the combined genetic and environmental modulation, has been reported in context of both obesity and asthma alone[@b16][@b17]. DNA methylation also plays a role in Th cell differentiation[@b18]. However, the potential dysregulation of DNA methylation associated with non-atopic Th-1 polarized systemic inflammation in obesity-associated asthma have not been investigated. To address this gap in knowledge, in a pilot study, we performed an epigenome-wide association study to investigate DNA methylation in Peripheral blood mononuclear cells (PBMCs) obtained from obese asthmatic children, comparing it to methylation in PBMCs from children with asthma alone, obesity alone and healthy control individuals. We hypothesized that obese asthmatic PBMCs have distinct epigenome-wide DNA methylation patterns that are associated with Th cell differentiation when compared to the other three study groups. We also proposed to study whether inflammatory pathways activated in the context of obesity-associated asthma are distinct from those activated in normal weight children with asthma and those with obesity alone. Although designed as a pilot study, our results are strongly suggestive of a role for the epigenome in mediating risk associated with obesity in the causation of asthma.

Results
=======

Study population
----------------

Demographic characteristics did not significantly differ between the four study groups ([Table 1](#t1){ref-type="table"}), other than mean weight and BMI z-score, in keeping with the study design. Asthma severity also did not differ between the obese asthmatics and normal-weight asthmatics (p = 0.7). Among obese asthmatics, 12.5% had intermittent, 37.5% had mild persistent, 25% had moderate persistent and 25% had severe persistent asthma while among normal-weight asthmatics, 25% had intermittent, 25% had mild persistent, 25% had moderate persistent and 25% had severe persistent asthma.

Epigenome-wide DNA methylation patterns in obese asthmatics compared to normal weight asthmatics, obese non-asthmatics and healthy controls
-------------------------------------------------------------------------------------------------------------------------------------------

DNA methylation profile in PBMCs from obese asthmatics was distinct from the profile in PBMCs from normal-weight asthmatics, obese non-asthmatics and healthy controls as seen on volcano plots ([Figure 1](#f1){ref-type="fig"}) and heat maps ([Figure 2a](#f2){ref-type="fig"}). While 7119 loci were differentially methylated in PBMCs from obese asthmatics compared to those from normal-weight asthmatics, 12,875 were differentially methylated compared to PBMCs from obese non-asthmatics and 6773 were differentially methylated when compared to healthy controls ([Figure 2b](#f2){ref-type="fig"}). Two hundred and fifteen loci were consistently differentially methylated in obese asthmatic PBMCs compared to the other three study groups. The top fifty differentially methylated promoter loci with an angle difference of greater than 20 (\~20% difference in methylation[@b19]) in PBMCs from obese asthmatics compared to those from normal-weight asthmatics, obese non-asthmatics and healthy controls are summarized in [Table 2](#t2){ref-type="table"},[3](#t3){ref-type="table"},[4](#t4){ref-type="table"}.

Cell to cell signaling and T lymphocyte differentiation were the primary functions of the genes targeted at their promoters for differential methylation that were identified by IPA analysis in PBMCs from obese asthmatics compared to normal-weight asthmatics and healthy controls ([Table 5](#t5){ref-type="table"}). Compared with normal-weight asthmatics and healthy controls, PBMCs from obese asthmatics had decreased methylation of gene promoters associated with Th cell differentiation (*ADAM17*, *LIF, NHEJ1*, *AHR, IL2RA, TBX21,* and *CCL5 (RANTES)*). Conversely, gene promoters of *FCER2 (CD23)*, a low affinity receptor for IgE and *TGFB1,* encoding for TGFβ, secreted by T regulatory cells (Tregs) that controls Th cell differentiation, were hypermethylated in PBMCs from obese asthmatics, compared to normal-weight asthmatics and healthy controls respectively, in keeping with the observed higher Th cell mediated inflammation[@b15][@b20]. Compared to obese non-asthmatics, genes encoding *CCL5, PGDR* and *PI3K,* known to influence chemotaxis of natural killer cells and macrophages were hypomethylated and *GNA12 and z*, members of the G protein family that are ubiquitous in the intracellular signaling pathways were hypermethylated in PBMCs from obese asthmatics.

Differentially methylated pathways in obesity associated asthma
---------------------------------------------------------------

To obtain information about the functional relevance of DNA methylation differences observed at the molecular level, we applied IPA to identify the canonical pathways selected for DNA methylation targeting in PBMCs from obese asthmatics compared to normal-weight asthmatics, obese non-asthmatics and healthy controls. In keeping with the gene functions identified to be modulated by DNA methylation, the primary canonical pathways found to be differentially methylated in PBMCs from obese asthmatics compared to normal-weight asthmatics including T cell signaling, and CCR5 signaling and nitric oxide and reactive oxygen release from macrophages ([Figure 3a](#f3){ref-type="fig"}). As compared to both PBMCs from obese non-asthmatics and healthy controls ([Fig. 3b and 3c](#f3){ref-type="fig"}), obese asthmatics had differential activation of pathways associated with 4-IBB signaling and regulation of activation of IL-2 expression on T lymphocytes. In addition to those discussed above, we retained other pathways in the figure as these pathways appear to be of physiologic significance and it would be interesting if the same pathways were enriched in a larger sample size.

In addition to canonical pathways, we also mapped the molecular interaction networks utilizing IPA software. In the network comparing obese asthmatics to normal-weight asthmatics, we found that while the IFNγ promoter itself was not differentially methylated, it was the hub of the enriched pathways and was associated with other differentially methylated factors ([Figure 4a](#f4){ref-type="fig"}). Further, while factors associated with known obesity-specific innate immune mechanisms (including *ALOX15, IGFB4, SOCS2* and *SOCS3)* were hypomethylated in obese non-asthmatics, obese asthmatics had evidence of hypomethylation of *IFNG, CCL5* and *PPARG* promoters, cytokines and transcription factors associated with both innate and non-atopic adaptive immunity ([Figure 4b](#f4){ref-type="fig"}). Similarly, as compared to healthy controls, promoters of *CCL5* and *CSF1* gene, associated with macrophage mediated inflammation and differentiation and survival respectively, was hypomethylated in PBMCs from obese asthmatics ([Figure 4c](#f4){ref-type="fig"}).

Discussion
==========

In this pilot study, we found evidence to support the hypothesis that PBMCs derived from pre-adolescent obese asthmatic minority children have distinct patterns of DNA methylation differing from those observed in PBMCs from normal weight asthmatics, obese non-asthmatics and healthy controls. There was decreased promoter methylation of a subset of genes that encode for molecules associated with innate immune and non-atopic patterns of inflammation, including *CCL5*[@b21], *IL2RA*[@b22]*,* and *TBX21*[@b23], a transcription factor associated with increased Th1 differentiation, while promoter methylation of *FCER* (CD23), a low affinity receptor for IgE[@b24] and of *TGFB1*, released by Tregs to control T cell mediated inflammation[@b25], was increased. Together, differential methylated molecules in PBMCs from obese asthmatic children were associated with pathways linked to T cell differentiation and increased macrophage activation, the two primary cell types that have been linked to the pathophysiology of obesity-associated asthma[@b20][@b26]. We have previously demonstrated that obesity-associated asthma is associated with Th1 polarization in this study sample, with increased Th1/Th2 cell ratio when compared to normal-weight asthmatics[@b15], providing a biological pathway for prior reports of non-atopic pattern of inflammation in obesity-associated asthma[@b13][@b27]. Epigenome wide methylation patterns found in the current study suggest that DNA methylation may play a role in the observed Th1 polarization among obese asthmatics.

We utilized an epigenome-wide methylation assay that yielded quantitative DNA methylation data on \~2.0 million loci. Previous studies performed in our laboratory using this technology have reported a strong correlation between genome-wide and single locus methylation[@b19][@b28][@b29], supporting the inferences drawn from the epigenome-wide studies. Our approach is different from those previously utilized in epigenetic studies done in context of asthma where single gene promoter methylation sites were studied among asthmatics using bisulphite MassArray or Pyrosequencing[@b30]. In addition to obtaining promoter-specific methylation data by our approach, we were able to obtain methylation profiles on other genes not routinely studied in the context of obesity or asthma. These methylation profiles were used to elucidate the interaction between the products of the differentially methylated genes, thereby identifying pathways that are modulated by DNA methylation and play a role in the inflammatory patterns observed among obese asthmatics. This information provides a more comprehensive insight into the complex interactions between inflammatory pathways activated by the co-existence of two chronic inflammatory conditions, asthma and obesity.

In keeping with the atopic phenotype of asthma among normal weight individuals, prior studies of DNA methylation profiles performed in asthmatics have found decreased methylation of IL-4 promoter and increased methylation of IFNγ promoter in adults[@b30] and children[@b31], confirming the role of methylation in naïve Th cell maturation[@b32] and in asthma. Differential methylation has correlated with cytokine production by the cells providing evidence of the functional implications of methylation[@b30][@b31]. Recently, using massively-parallel sequencing, Kim et.al. have demonstrated differential methylation in bronchial mucosa from atopic adults with asthma compared to non-atopic asthmatics, providing additional support for the role of DNA methylation in asthma pathogenesis[@b33]. Consistent with our findings of Th1 polarization with lower serum levels of IL-13 and higher levels of IL-6 and TNFα, as well as higher Th1/Th2 cell ratio in obese asthmatic pre-adolescent children[@b15], we found hypomethylation of *CCL5,* a pro Th1 chemokine[@b21] that has strong chemotaxis not only for naïve and memory T cells but also for macrophages, the primary cell associated with obesity mediated inflammation[@b34]. Similarly, *TBX21,* a transcription factor involved in selective differentiation of naïve Th cells into Th1 cells[@b23] was also hypomethylated in PBMCs from obese asthmatics relative to healthy controls. However, since similar differences in *TBX21* methylation were not observed between obese and normal-weight asthmatics, it is possible that differential methylation of other pathways, such as those mediated by GATA3, a Th2 transcription factor or downstream molecules such as IL-4, IL-5 or IL-13, may also play a role in the observed Th1 polarization among obese asthmatics relative to normal-weight asthmatics. Conversely, there was evidence of hypermethylation of IgE receptor CD23[@b24] in obese asthmatics compared to normal-weight asthmatics. CD23 is proposed to play a role in antigen presentation and regulation of immune responses, particularly with enhancement of IgE mediated T and B cell responses[@b24]. Together these results provide evidence that observed patterns of DNA methylation likely play a role in non-atopic inflammatory phenotype of obesity-associated asthma.

Stefanowicz et al.[@b35] recently demonstrated cell-specific methylation differences in context of asthma and atopy, a systemic disease, highlighting the need for simultaneous investigation of DNA methylation in cells obtained from systemic circulation and from disease-targeted organs. They, however, did not find any significant methylation differences in PBMCs obtained from asthmatics and healthy controls, findings that differ from our observations. There may be several factors contributing to the observed differences. There were inherent differences in the technique used to elucidate methylation patterns. While our method using DNA methylation specific restriction enzymes followed by ligation mediated PCR amplification allows the study of \~2 million loci, Stefanowicz et al. investigated methylation at 1505 loci on bisulphite treated DNA using a cancer panel, potentially limiting their ability to identify differential methylation at several additional loci. Moreover, our study cohort included older children, so inherent differences in age, as well as potential differences in ethnicity and asthma severity between the two study samples may offer additional explanations for the differences. Prior studies investigating the influence of ethnicity on clinical phenotypes have identified ethnicity-specific single nucleotide polymorphisms that correlate with clinical parameters including peripheral white cell counts[@b36] and disease such as multiple sclerosis[@b37]. Whether similar ethnicity-specific differences in the epigenome are associated with disease incidence and severity needs further investigation.

Macrophages are the primary cell type linked to obesity-mediated inflammation[@b34]. Recent studies have demonstrated that alveolar macrophages in adult obese asthmatics are of the pro-inflammatory phenotype that can be activated by leptin alone[@b26]. We found that PBMCs from obese non-asthmatics had evidence of decreased promoter methylation of several proteins including *ALOX15*, *IGFBP4, SOCS2 and SOCS3* that are associated with obesity-specific activation of innate immune pathways[@b38]. However, in PBMCs from obese asthmatics, key cytokines and inflammatory mediators released by macrophages and involved in monocyte chemotaxis, and proliferation and survival including *CCL5* and *CSF1,* and downstream molecules such as *PI3K* involved in T cell differentiation[@b39], signal transduction, and NFκB pathway[@b40] were hypomethylated compared to obese non-asthmatics, and healthy controls, together supporting a greater role of macrophage-mediated inflammation in childhood obesity-associated asthma, relative to children with obesity alone and healthy controls. Given that obesity-mediated inflammation is primarily driven by leptin[@b11] and leptin levels in our cohort were higher among obese asthmatics than obese non-asthmatics[@b15], we speculate that DNA methylation may be one mechanism by which leptin may be influencing macrophage function and systemic inflammation among obese asthmatics. In keeping with the complex biological pathways influenced by methylation, while systemic Th1 polarization was observed in obese asthmatic children[@b15], IFNγ promoter itself was not differentially methylated in obese asthmatics compared to normal-weight asthmatics. We observed that other differentially methylated molecules indirectly related with IFNγ promoter and maybe altered the IFNγ pathway but the extent to which these potentially played a role in the Th1 polarization by modulating IFNγ production needs further investigation.

This study has a small sample size and only represents a first attempt to determine whether epigenetic changes are involved in obesity-associated asthma, with limited power to detect anything but the strongest and most consistent changes. Furthermore, we recognize that our use of mixed PBMCs, comprised of T cells, B cells and monocytes, reduces our ability to detect T cell-specific changes. To have generated data indicative of systematic changes occurring at loci with properties consistent with a role in asthma and obesity indicates that this avenue is worth pursuing further, and that epigenome-wide DNA methylation analysis can identify additional genes which may orchestrate the observed inflammatory patterns needs additional investigation. These results suggest that DNA methylation influences several genes that together determine the phenotype associated with a particular disease. As recently highlighted[@b41], identification of a pathway in addition to methylation differences at a single gene level is needed to better define the pathophysiologic mechanisms associated with pulmonary disease and identify key biomarkers that may be amenable to pharmacologic intervention, given the reversible nature of DNA methylation[@b42]. We also recognize the lack of gene expression studies, due to limited number of PBMCs, limits the extrapolation of our results into biological consequences. However, since we had previously observed a Th1 polarized phenotype in the same samples that underwent quantification of DNA methylation, our current results provide a foundation for potential role of DNA methylation in Th1 polarization in obese asthmatics, and provide pilot data for future studies to validate our findings with gene expression studies. Given our small sample size, our results are also susceptible to by-chance findings. Hence, future studies of DNA methylation patterns of individual cell types combined with gene expression studies within the peripheral blood mononuclear cells are needed to better determine the role of methylation in the differentiation and activation of each immune cell in obese asthmatics.

In conclusion, in a pilot study investigating DNA methylation patterns among obese asthmatic pre-adolescent children compared to those with asthma alone, obesity alone and healthy controls, we found that methylation patterns in peripheral blood mononuclear cells in obesity-associated asthma are distinct and are indicative of activation of innate and adaptive immune responses, including T cell differentiation, and release of pro-inflammatory substances from macrophages. Although both obesity and obesity-associated asthma have similar inflammatory profiles with systemic non-atopic inflammation, the DNA methylation patterns suggest inherent differences with activation of distinct inflammatory pathways in obese asthmatics. Further studies are needed to investigate which cell types are contributing to the observed methylation patterns, and to confirm and validate our findings.

Methods
=======

Study material and ethics statement
-----------------------------------

Peripheral blood samples used to study genome-wide methylation were a subgroup of samples obtained from pre-adolescent minority children participating in a study investigating inflammatory patterns in obesity-associated asthma[@b15]. This subgroup consisted of samples from 32 children, including 8 from each of the 4 study groups of obese asthmatics, normal-weight asthmatics, obese non-asthmatics and healthy controls where the parent/legal guardian of the participating child had given written informed consent for use of the residual PBMCs for future studies. As previously described, obesity was defined as a body mass index (BMI) greater than 95th percentile for age and normal-weight as BMI less than the 85th percentile[@b15]. Asthmatics were those diagnosed by their primary care physicians, as per the National Asthma Education and Prevention Program (NAEPP) guidelines[@b43]. Co-existence of atopic conditions including allergic rhinitis and eczema did not differ between the two study groups with asthma. The characteristics of the subgroup including demographics and asthma severity did not differ from those of the parent study. The Institutional Review Board at Montefiore Medical Center approved the parent study as well as the use of residual de-identified samples for the current study.

The Ficoll-Hypaque method was used to isolate peripheral blood mononuclear cells (PBMCs) from whole blood, the purity of which was confirmed by flow cytometry \[[Figure S1](#s1){ref-type="supplementary-material"}\]. The cells were aliquoted, frozen in 10% DMSO, and stored in liquid nitrogen until further processing. Genomic DNA was isolated from aliquots of 3 × 10^6^ PBMCs using Gentra Puregene Blood kit (Qiagen, Chatsworth, CA) following the manufacturer\'s instructions.

HELP-tagging assay to test DNA methylation
------------------------------------------

Epigenome-wide methylation studies in PBMCs from the four study groups were performed by using the massively-parallel sequencing (MPS)-based HELP-tagging assay on the genomic DNA as previously reported[@b44][@b45]. Briefly, 5 μg of genomic DNA was digested by HpaII and purified by phenol/chloroform extraction followed by ethanol precipitation. The digested DNA was then ligated at the cohesive end to the first adaptor including a restriction enzyme site that was digested by EcoP151 followed by ligation of the second adaptor that was MPS compatible. These adaptors served as priming sites for ligation-mediated PCR amplification. Further, to generate longer flanking sequences, a T7 polymerase was added followed by a reverse transcription step, allowing the generation of libraries for MPS that were compared to human MspI reference libraries. Libraries were sequenced using Illumina Genome GAIIx/HiSeq 2000 sequencer following the manufacturer\'s instructions.

While MspI digestion is methylation insensitive and cuts the DNA at all CCGG sites, HpaII digestion is methylation sensitive, and cuts DNA only at CCGG sites where the central CG is unmethylated at the cytosine nucleotide. Comparison of HpaII count to MspI count for each locus thereby allows quantification of methylation. The angle obtained by plotting HpaII count on the y-axis and MspI count on the x-axis provides a quantitative measure of locus-specific methylation. A higher angle formed when HpaII count is high relative to MspI is evidence of relative hypomethylation while a smaller angle is evidence of hypermethylation[@b19]. Prior studies in our lab have demonstrated a correlation of \~0.9 between replicates and between angle values obtained by HELP-tagging and quantification of methylation by bisulphite MassArray (Sequenom)[@b19][@b28][@b29].

Library quality assessment
--------------------------

As described by Jing et al.[@b45], the Illumina genome analyzer uses the CASAVA software to perform image analysis and base calling, the outputs from which are the raw sequence reads in Illumina\'s QSEQ format. For quality assessment of the sequences, each noncallable (unknown) base represented as a period is converted to "N", which are statistically analyzed to assess sequencing success and individual cycle efficacy. The library quality is further assessed by determining the proportion and position of the 3′ adaptor sequence within the reads, where the first two CG represent the cohesive end for ligation of HpaII digestion products, and the other six nucleotides are the EcoP151 recognition site. A high percent of reads containing the adaptor sequence starting at position 27 is indicative of a high quality library. By removing sequences with excessive tracts of unknown bases ("N"s) and those lacking the adaptor sequence, spurious sequences are eliminated. Of the remaining sequences, the first base is removed since it originated from the 3′ adaptor ligation and the 5′ adaptor is masked by replacing the bases with "N"s to maintain a uniform tag size. Illumina\'s alignment algorithm, ELAND, treats unknown ("N") bases as wild cards and therefore does not penalize them during alignment to the reference genome. During the alignment, a maximum of two mismatches are allowed and insertion/deletions are ignored. Statistics generated from the alignment include details on rejection of sequences that had greater than 10 aligned hits and those with no match at all, retaining only those that had unique or fewer than 10 aligned hits that were mapped to an annotated HpaII site. The counts of sequence tags aligned adjacent to every HpaII/MspI site are assessed. Tags that align to more than one locus are given a proportional count. Cumulative HpaII counts are normalized with MspI counts for each HpaII/MspI annotated site. To quantify methylation, the normalized accumulative proportional (NAP) count for the HpaII digested sample and the MspI reference sample are represented as Cartesian coordinates for vectors projected in two dimensional space where the Y axis represents the HpaII NAP count and the X-axis represents the MspI NAP count. Represented as a vector, the direction (angle relative to the origin) corresponds to quantification of hypomethylation. These angle values are then linear scaled to a range from 0 to 100 and stored as WIG files[@b45]. On an average, methylation status of 1.8 × 10^6^ loci is obtained per sample.

Data snalysis
-------------

Demographic characteristics of the study population were analyzed using STATA statistical software version 10 (StataCorp, College Station, TX). DNA methylation results were analyzed using R (version 2.12.0 (<http://www.R-project.org>). The MPS output was pre-processed and underwent normalization for total count numbers as described above. The locus-specific angle obtained by plotting HpaII against MspI was compared between obese asthmatics and normal weight asthmatics, obese non-asthmatics and healthy controls, using paired T-test. The small sample size in this pilot study does not allow us to set a False Discovery Rate, or adjust for multiple testing. We therefore analyzed the biological significance of the top 2 × 10^4^ or the top 1% most consistently differentially methylated loci in obese asthmatics compared to normal-weight asthmatics, obese non-asthmatics and healthy controls in which differential methylation were defined as an absolute difference of angle value of \>20, corresponding to \~20% difference in methylation. We report the locus-specific differential methylation in obese asthmatics compared to the other three study groups. Differentially methylated loci were defined in terms of genomic context (*e.g.,* occurring in a gene promoter, defined as ± 1000 base pairs from the transcription start site). All p values reported are two tailed with statistical significance set *a priori* at 0.05. All data are available through the Gene Expression Omnibus database (accession number GEO:GSE43705).

Ingenuity pathway analysis
--------------------------

The biologic function application of Ingenuity Pathway Analysis software (IPA, [www.ingenuity.com](http://www.ingenuity.com), Redwood City, CA) was used to investigate whether differentially methylated gene promoters were enriched for specific functional relationships. The analysis was filtered to human genes and to immune cells. Canonical pathway identification was filtered to those associated with cellular or humoral immune response, or cytokine signaling. Differentially methylated gene promoters in obese asthmatic PBMCs associated most strongly with functional networks relevant to cell to cell signaling when compared to normal weight asthmatics, chemotaxis of natural killer (NK) cells when compared to obese non-asthmatic and differentiation of T lymphocytes when compared to healthy control PBMCs. Graphic representation of the canonical pathways and the functional networks was obtained from IPA.
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![Volcano plots comparing DNA methylation in obese asthmatics (OA) to (a).\
Normal-weight Asthmatics (NwA) (b). Obese non-asthmatics (Ob) and (c). Healthy Controls (HC) (plot of loci specific methylation differences (x-axis) vs. −log~10~p value (y-axis). The red dots represent the top 1% loci where the methylation difference between the two study groups was greater than 20.](srep02164-f1){#f1}

![(a). Heat maps of methylation differences discriminating obese asthmatics (OA) from (A) normal weight asthmatics (NwA), (B) obese non-asthmatics (Ob) and (C) healthy controls (HC). Red indicates more methylation and yellow less methylation by HELP-tagging. The columns represent subjects in each study group while the rows are the loci where the methylation difference between the two study groups being compared was greater than 20. (b). Proportional Venn diagram depicting overlap of differentially methylated CpG sites identified when obese asthmatics (OA) were compared to (A) normal-weight asthmatics (NwA), (B) Obese non-asthmatics (Ob) and (C) healthy controls (HC). Two hundred and fifteen loci were consistently differentially methylated in obese asthmatics compared to the other three groups.](srep02164-f2){#f2}

![(a). Canonical pathways differentially methylated between obese asthmatics and normal-weight asthmatics. T cell and macrophage signaling and macrophage activation were the primary canonical pathways differentially methylated between obese and normal-weight asthmatics. (b). Canonical pathways differentially methylated between obese asthmatics and obese non-asthmatics. Macrophage activation and T cell signaling were the primary canonical pathways differentially methylated between obese asthmatics and obese non-asthmatics. (c). Canonical pathways differentially methylated between obese asthmatics and healthy controls. Macrophage activation, T cell signaling and IL-15 mediated natural killer (NK) cell modulated Th cell activation were the primary canonical pathways differentially methylated between obese asthmatics and healthy controls.](srep02164-f3){#f3}

![(a). Network of differentially methylated molecules in obese asthmatics compared to normal-weight asthmatics. Genes encoding for molecules in red nodes are hypomethylated in obese asthmatics while those in green nodes are hypermethylated relative to normal weight asthmatics. (b). Network of differentially methylated molecules in obese asthmatics compared to obese non-asthmatics. Genes encoding for molecules in red are hypomethylated in obese asthmatics while those in green are hypermethylated relative to obese non-asthmatics. The nodal relationships indicated in solid lines denote direct while those in dashed lines denote indirect interactions. The shape of each node denotes the molecule class: horizontal ovals are transcription factors, vertical ovals are transmembrane receptors, horizontal diamonds are peptidases, vertical diamonds are enzymes, squares are growth factors, horizontal rectangles are nuclear receptors, vertical rectangles are ion channels, inverted triangles are kinases, and circles are "other" molecules. (c). Network of differentially methylated molecules in obese asthmatics compared to healthy controls. Genes encoding for molecules in red are hypomethylated in obese asthmatics while those in green are hypermethylated relative to healthy controls. The nodal relationships indicated in solid lines denote direct while those in dashed lines denote indirect interactions. The shape of each node denotes the molecule class: horizontal ovals are transcription factors, vertical ovals are transmembrane receptors, horizontal diamonds are peptidases, vertical diamonds are enzymes, squares are growth factors, horizontal rectangles are nuclear receptors, vertical rectangles are ion channels, inverted triangles are kinases, and circles are "other" molecules.](srep02164-f4){#f4}

###### Characteristics of the study population

  Variable\*                            Obese asthmatics   Normal-weight asthmatics   Obese non-asthmatics   Healthy controls   P value
  ------------------------------------ ------------------ -------------------------- ---------------------- ------------------ ---------
  Age (years)                               9.1±1.4                8.1±1.2                  9.3±1.3              8.3±1.4         0.07
  Weight (kgs)                             51.4±15.7               32.3±7.4                48.2±10.8             33.2±6.3       \<0.01
  BMI z score                                2±0.5                 0.6±1.2                  1.7±0.4              0.7±0.5        \<0.01
  Gender (M:F)                                3:5                    3:5                      4:4                  3:5            0.6
  Ethnicity (H:AA)                            3:5                    3:5                      4:4                  3:5            0.6
  Percent predicted FEV~1~/FVC ratio        82.6±5.4               87.9±5.1                 89.4±3.6             89.9±6.7        0.048

BMI body mass index, M male, F female, H Hispanic, AA African-American.

Age, weight, BMI z-score and percent predicted FEV~1~/FVC ratio are reported as mean±SD.

###### Top fifty promoter loci with differential methylation between obese asthmatics and normal weight asthmatics

  ID                       Symbol                                  Entrez Gene Name                                Methylation HpaII angle difference
  ---------------------- ----------- ---------------------------------------------------------------------------- ------------------------------------
  Hypermethylated loci                                                                                            
  NM_032808                LINGO1                   leucine rich repeat and Ig domain containing 1                               −26.75
  NM_002457                 MUC2                        mucin 2, oligomeric mucus/gel-forming                                    −30.20
  NM_175875                 SIX5                                    SIX homeobox 5                                               −30.22
  NM_000674                ADORA1                               adenosine A1 receptor                                            −30.82
  NM_012212                 PTGR1                             prostaglandin reductase 1                                          −36.04
  NM_004292                 RIN1                               Ras and Rab interactor 1                                          −36.58
  NM_030923                TMEM163                            transmembrane protein 163                                          −36.66
  NR_023315                 ASZ1           ankyrin repeat, SAM and basic leucine zipper domain containing 1                      −37.41
  NM_016396                CTDSPL2         CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A)                       −39.70
  NM_000577                 IL1RN                         interleukin 1 receptor antagonist                                      −41.41
  NM_005514                 HLA-B                    major histocompatibility complex, class I, B                                −46.27
  NM_004979                 KCND1         potassium voltage-gated channel, Shal-related subfamily, member 1                      −46.61
  NM_002002                 FCER2              Fc fragment of IgE, low affinity II, receptor for (CD23)                          −47.49
  NM_003327                TNFRSF4               tumor necrosis factor receptor superfamily, member 4                            −46.31
  NM_002617                 PEX10                          peroxisomal biogenesis factor 10                                      −47.88
  NM_014700               RAB11FIP3                 RAB11 family interacting protein 3 (class II)                                −48.80
  NM_139172                TMEM190                            transmembrane protein 190                                          −50.02
  NM_006667                PGRMC1                     progesterone receptor membrane component 1                                 −51.12
  NM_032790                 ORAI1                 ORAI calcium release-activated calcium modulator 1                             −51.61
  NM_002384                 MBD1                         methyl-CpG binding domain protein 1                                     −53.69
  NM_016396                CTDSPL2         CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A)                       −54.03
  NM_020343               RALGAPA2            Ral GTPase activating protein, alpha subunit 2 (catalytic)                         −54.91
  NM_022143                 LRRC4                          leucine rich repeat containing 4                                      −58.71
  NM_024617                ZCCHC6                       zinc finger, CCHC domain containing 6                                     −59
  NM_001769                  CD9                                     CD9 molecule                                                −63.28
  Hypomethylated loci                                                                                             
  NM_004356                 CD81                                    CD81 molecule                                                22.89
  NM_005905                 SMAD9                                SMAD family member 9                                            24.21
  NM_002985                 CCL5                            chemokine (C-C motif) ligand 5                                       25.65
  NM_006202                 PDE4A                        phosphodiesterase 4A, cAMP-specific                                     25.78
  NM_198836                 ACACA                            acetyl-CoA carboxylase alpha                                        30.10
  NM_006253                PRKAB1            protein kinase, AMP-activated, beta 1 non-catalytic subunit                         30.29
  NM_000229                 LCAT                         lecithin-cholesterol acyltransferase                                    30.45
  NM_181524                PIK3R1              phosphoinositide-3-kinase, regulatory subunit 1 (alpha)                           32.71
  NM_024782                 NHEJ1                         nonhomologous end-joining factor 1                                     35.34
  NM_000283                 PDE6B                   phosphodiesterase 6B, cGMP-specific, rod, beta                               35.76
  NM_017617                NOTCH1                                      notch 1                                                   38.86
  NM_007161                 LST1                           leukocyte specific transcript 1                                       42.42
  NM_016592                 GNAS                                  GNAS complex locus                                             42.82
  NM_006601                PTGES3                       prostaglandin E synthase 3 (cytosolic)                                   42.85
  NM_002641                 PIGA               phosphatidylinositol glycan anchor biosynthesis, class A                          47.80
  NM_003540               HIST1H4A                              histone cluster 1, H4a                                           47.36
  NM_001807                  CEL                 carboxyl ester lipase (bile salt-stimulated lipase)                             47.79
  NM_016541                 GNG13              guanine nucleotide binding protein (G protein), gamma 13                          47.74
  NM_030928                 CDT1                   chromatin licensing and DNA replication factor 1                              48.15
  NM_213604               ADAMTSL5                                  ADAMTS-like 5                                                50.41
  NM_022143                 LRRC4                          leucine rich repeat containing 4                                      52.43
  NM_006668                CYP46A1              cytochrome P450, family 46, subfamily A, polypeptide 1                           56.03
  NM_002079                 GOT1                         glutamic-oxaloacetic transaminase 1,                                    56.28
  NM_013361                ZNF223                              zinc finger protein 223                                             61
  NM_003073                SMARCB1    SWI/SNF related, matrix associated, actin dependent regulator of chromatin                 64.52

###### Top fifty promoter loci with differential methylation between obese asthmatics and obese non-asthmatics

  ---------------------- --------------------- ------------------------------------------------------------------------- ------------------------------------
  ID                            Symbol                                     Entrez Gene Name                               Methylation HpaII angle difference
  Hypermethylated loci                                                                                                   
  NM_000101                      CYBA                             cytochrome b-245, alpha polypeptide                                   −21.66
  NM_006961                      ZNF19                                  zinc finger protein 19                                          −22.11
  NM_015470                    RAB11FIP5                     RAB11 family interacting protein 5 (class I)                               −22.53
  NM_000755                      CRAT                                carnitine O-acetyltransferase                                      −26.18
  NM_004064                     CDKN1B                     cyclin-dependent kinase inhibitor 1B (p27, Kip1)                             −28.04
  NM_080649                      APEX1                    APEX nuclease (multifunctional DNA repair enzyme) 1                           −28.60
  NM_004791                     ITGBL1                   integrin, beta-like 1 (with EGF-like repeat domains)                           −29.08
  NM_006743                      RBM3                           RNA binding motif (RNP1, RRM) protein 3                                 −29.72
  NM_005054                      RGPD5                         RANBP2-like and GRIP domain containing 5                                 −31.06
  NM_002208                      ITGAE            integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen)                   −33.12
  NM_002002                      FCER2                 Fc fragment of IgE, low affinity II, receptor for (CD23)                         −35.03
  NM_019625                      ABCB9                  ATP-binding cassette, sub-family B (MDR/TAP), member 9                          −36.66
  NM_152740                     HIBADH                            3-hydroxyisobutyrate dehydrogenase                                    −39.92
  NM_006332                      IFI30                          interferon, gamma-inducible protein 30                                  −43.98
  NM_183240                     TMEM37                                 transmembrane protein 37                                         −44.07
  NM_001805                      CEBPE                      CCAAT/enhancer binding protein (C/EBP), epsilon                             −44.37
  NM_005037                      PPARG                     peroxisome proliferator-activated receptor gamma                             −44.94
  NM_002774                      KLK6                               kallikrein-related peptidase 6                                      −45.46
  NM_003486                     SLC7A5          solute carrier family 7 (amino acid transporter light chain, L system),                 −47.79
  NM_033023                      PDGFA                     platelet-derived growth factor alpha polypeptide                             −48.40
  NM_024552                      CERS4                                    ceramide synthase 4                                           −48.55
  NM_004104                      FASN                                     fatty acid synthase                                           −49.08
  NM_006793                      PRDX3                                      peroxiredoxin 3                                             −51.71
  NM_172364                    CACNA2D4               calcium channel, voltage-dependent, alpha 2/delta subunit 4                       −57.17
  NM_004472                      FOXD1                                      forkhead box D1                                             −61.60
  Hypomethylated loci                                                                                                    
  NM_003513               HIST1H2AB/HIST1H2AE                           histone cluster 1, H2ae                                         24.78
  NM_080816                      SIRPG                              signal-regulatory protein gamma                                     26.70
  NM_001374                    DNASE1L2                               deoxyribonuclease I-like 2                                        26.96
  NR_023391                    CYP4F30P           cytochrome P450, family 4, subfamily F, polypeptide 30, pseudogene                    29.46
  NM_005003                     NDUFAB1            NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8kDa                    30.03
  NM_005265                      GGT1                                 gamma-glutamyltransferase 1                                       30.76
  NM_002718                     PPP2R3A                   protein phosphatase 2, regulatory subunit B″, alpha                           31.16
  NM_020686                      ABAT                              4-aminobutyrate aminotransferase                                     31.99
  NM_002066                       GML                 glycosylphosphatidylinositol anchored molecule like protein                       35.78
  NM_001444                      FABP5                    fatty acid binding protein 5 (psoriasis-associated)                           35.79
  NM_181524                     PIK3R1                  phosphoinositide-3-kinase, regulatory subunit 1 (alpha)                         36.31
  NM_002745                      MAPK1                            mitogen-activated protein kinase 1                                    36.33
  NM_005855                      RAMP1                 receptor (G protein-coupled) activity modifying protein 1                        39.95
  NM_012461                      TINF2                         TERF1 (TRF1)-interacting nuclear factor 2                                42.13
  NM_005037                      PPARG                     peroxisome proliferator-activated receptor gamma                             44.94
  NM_000498                     CYP11B2                 cytochrome P450, family 11, subfamily B, polypeptide 2                            45
  NM_178011                     LRRTM3                       leucine rich repeat transmembrane neuronal 3                               45.43
  NM_005063                       SCD                        stearoyl-CoA desaturase (delta-9-desaturase)                               47.58
  NM_007161                      LST1                               leukocyte specific transcript 1                                     48.37
  NM_004566                     PFKFB3                   6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3                          52.96
  NR_026790                      HCG11                                   HLA complex group 11                                           53.02
  NM_013361                     ZNF223                                  zinc finger protein 223                                         55.25
  NM_173821                     CXXC11                                  CXXC finger protein 11                                          55.43
  NM_006099                      PIAS3                          protein inhibitor of activated STAT, 3                                  55.46
  NM_017693                      BIVM                    basic, immunoglobulin-like variable motif containing                           56.67
  NM_015320                     ARHGEF4                     Rho guanine nucleotide exchange factor (GEF) 4                              71.73
  ---------------------- --------------------- ------------------------------------------------------------------------- ------------------------------------

###### Top fifty promoter loci with differential methylation between obese asthmatics and healthy controls

  ---------------------- ----------- ---------------------------------------------------------------------------------- ------------------------------------
  ID                       Symbol                                     Entrez Gene Name                                   Methylation HpaII angle difference
  Hypermethylated loci                                                                                                  
  NM_005004                NDUFB8                    NADH dehydrogenase (ubiquinone) 1 beta subcomplex                                 −21.89
  NM_016538                 SIRT7                                        sirtuin 7                                                     −27.80
  NM_017675                 CDHR2                             cadherin-related family member 2                                         −35.42
  NM_178496                MB21D2                                Mab-21 domain containing 2                                            −36.33
  NM_002896                 RBM4                                RNA binding motif protein 4                                            −38.57
  NM_000422                 KRT17                                        keratin 17                                                    −43.98
  NM_002774                 KLK6                               kallikrein-related peptidase 6                                          −44.02
  NM_012338                TSPAN12                                     tetraspanin 12                                                  −44.49
  NM_181553                 CMTM3                    CKLF-like MARVEL transmembrane domain containing 3                                −44.46
  NM_052885                SLC2A13          solute carrier family 2 (facilitated glucose transporter), member 13                       −47.89
  NM_182527                 CABP7                                calcium binding protein 7                                             −48.07
  NM_024641                 MANEA                                 mannosidase, endo-alpha                                              −48.67
  NM_006907                 PYCR1                           pyrroline-5-carboxylate reductase 1                                        −49.26
  NM_052910                SLITRK1                          SLIT and NTRK-like family, member 1                                        −52.37
  NM_198570                 VWC2                        von Willebrand factor C domain containing 2                                    −52.42
  NM_138973                 BACE1                             beta-site APP-cleaving enzyme 1                                          −55.56
  NM_014578                 RHOD                                ras homolog family member D                                            −55.69
  NM_001329                 CTBP2                               C-terminal binding protein 2                                           −56.93
  NR_027052               THAP7-AS1                      THAP7 antisense RNA 1 (non-protein coding)                                    −57.29
  NM_001332                CTNND2                          catenin (cadherin-associated protein),                                      −57.40
  NM_006234                POLR2J                     polymerase (RNA) II (DNA directed) polypeptide J                                 −57.44
  NM_001395                 DUSP9                              dual specificity phosphatase 9                                          −57.75
  NM_005938                 FOXO4                                     forkhead box O4                                                  −58.65
  NM_001880                 ATF2                             activating transcription factor 2                                         −62.41
  NM_020781                ZNF398                                 zinc finger protein 398                                              −68.76
  Hypomethylated loci                                                                                                   
  NM_001571                 IRF3                               interferon regulatory factor 3                                          20.49
  NM_172241                CTAGE1                      cutaneous T-cell lymphoma-associated antigen 1                                  20.50
  NM_006290                TNFAIP3                     tumor necrosis factor, alpha-induced protein 3                                  21.22
  NM_014898                 ZFP30                              zinc finger protein 30 homolog                                          22.13
  NM_000131                  F7                                    coagulation factor VII                                              22.74
  NM_003463                PTP4A1                     protein tyrosine phosphatase type IVA, member 1                                  23.28
  NM_024693                ECHDC3                         enoyl CoA hydratase domain containing 3                                      25.56
  NR_026918                 PTPN3                    protein tyrosine phosphatase, non-receptor type 3                                 26.80
  NM_005905                 SMAD9                                   SMAD family member 9                                               27.19
  NR_001297               PCDHGB8P                     protocadherin gamma subfamily B, 8 pseudogene                                   27.35
  NM_031849                PCDHA6                                  protocadherin alpha 6                                               28.97
  NM_014632                MICAL2                           microtubule associated monoxygenase,                                       32.76
  NM_014330               PPP1R15A                     protein phosphatase 1, regulatory subunit 15A                                   34.37
  NR_003716                HOTAIR                               HOX transcript antisense RNA                                           35.79
  NM_178012                TUBB2B                                tubulin, beta 2B class IIb                                            37.26
  NM_178172                GPIHBP1    glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1                 38.18
  NM_015257               TMEM194A                               transmembrane protein 194A                                            38.31
  NM_001276                CHI3L1                      chitinase 3-like 1 (cartilage glycoprotein-39)                                  41.25
  NM_000853                 GSTT1                            glutathione S-transferase theta 1                                         41.85
  NM_145726                 TRAF3                             TNF receptor-associated factor 3                                         51.74
  NR_021485                EGFEM1P                          EGF-like and EMI domain containing 1                                       55.82
  NM_020713                ZNF512B                                zinc finger protein 512B                                             58.40
  NM_013361                ZNF223                                 zinc finger protein 223                                              58.42
  NM_024014                 HOXA6                                       homeobox A6                                                    59.92
  NM_052945               TNFRSF13C                tumor necrosis factor receptor superfamily, member 13C                              64.29
  ---------------------- ----------- ---------------------------------------------------------------------------------- ------------------------------------

###### Molecules with differentially methylated gene promoters and their associated cellular functions in obese asthmatics (OA) compared to a) normal weight asthmatics (NwA), b) obese non-asthmatics (Ob) and c) healthy controls (HC)

  OA vs NwA                                                                                                                                                                                                OA vs Ob                                                                                                                           OA vs HC
  -------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------
  Hypomethylated gene promoters                                                                                                                                                                 Hypomethylated gene promoters                                                                                                      Hypomethylated gene promoters
  a\. Adam metallopeptidase domain (*ADAM17*) (pro-inflammatory enzyme causing ectodomain shedding of IL6 and TNFα)[@b46]                                                                                 a\. *CCL5*                                                                                                                        a\. *ADAM17*
  b\. Interleukin 2 receptor alpha (*IL2RA*) (member of high-affinity receptor for IL2, associated with increased Th1 differentiation)[@b22]           b\. Prostaglandin D2 receptor (*PGDR*) (Regulates prostagladin D mediated mast cell and Th cell responses)[@b53]                                                                     b\. *IL2RA*
  c\. Interleukin 27 (*IL27*) (induces maturation of T regulatory cells)[@b47]                                                                             c\. G protein alpha 11 (*GNA11*) (involved in receptor mediated activation of signaling pathways)[@b54]                                                                           c\. *AHR*
  d\. Leukemia inhibitory factor (*LIF*) (Proliferation of mature T cells)[@b48]                                                                d\. Phosphatidol inositol 3 kinase (*PI3K*) (involved in activation of signaling pathways)[@b39]Hypermethylated gene promoters                       d\. T box transcription factor (*TBX21)* (Th1 lineage defining transcription factor)[@b23]
  e\. Non homologous end joining factor 1 (*NHEJ1*) (associated with DNA repair; deficiency linked to immunodeficiency)[@b49]                              e\. G protein alpha 12 (*GNA12*) (involved in receptor mediated activation of signaling pathways)[@b54]                                      e\. PRELI domain 1 (expressed in peripheral B lymphocytes and regulates STAT6)[@b56]
  f\. chemokine (C-C motif) ligand 5 (*CCL5*) (chemoattractant for mast cells, memory T cells)[@b21]Hypermethylated gene promoters                    f\. G protein alpha z polypeptide (*GNAz*) (involved in receptor mediated activation of signaling pathways)[@b54]                                                                      f\. *CCL5*
  g\. Aryl hydrocarbon receptor (*AHR*)(regulates immune system, and cellular proliferation and migration)[@b50]                                          g\. TNF receptor superfamily 1B (*TNFSRF1B*) (increased T cell and macrophage related inflammation)[@b52]              g\. Colony stimulating factor 1 receptor *(CSF1R)* (macrophage production and differentiation)[@b57]Hypermethylated gene promoters
  h\. Chromodomain helicase DNA binding protein (*CHD*)[@b51]                                                                                           h\. IFNγ receptor 1 (*IFNGR1*)(binding site for IFNγ, site for interaction between monocytes and Tcells)[@b55]                                                                       h\. *CHD*
  i\. TNF receptor superfamily 4 (*TNFSRF4*) (regulate development of memory and effector Tcells)[@b52]                                                                            i\. FcεRII (*FCER*), low affinity receptor for IgE[@b24]                                                          i\. TGF beta (*TGFB1*) (produced by T regulatory cells to regulate immune responses)[@b25]
  j\. TNF receptor superfamily 9 (*TNFSRF9*) (activation of mast cells, CD4+ and CD8+ cells)[@b52]                                                                                                                                                                                                                                         j\. *TNFRSF4*
  k\. FcεRII (*FCER*), low affinity receptor for IgE[@b24]                                                                                                                                                                                                                                                                                        
